New analysis shows tirzepatide consistently reduces bodyweight regardless of body mass index (BMI) before treatment
*Note – this is an early press release from the European Congress on Obesity in Venice, Italy 12-15 May. Please credit the congress when using this research*
Tirzepatide, a medication authorised to treat obesity and/or type 2 diabetes, consistently reduces bodyweight regardless of the patient’s body mass index (BMI before treatment), from the range of overweight to class III obesity. The study, to be presented at this year’s European Congress on Obesity (Venice, Italy, 12-15 May) is by Prof Carel Le Roux, University ...












